ArticleNAR cancer2026

Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors.

Lauryn Buckley-Benbow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.